FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Parlati Francesco

2. Date of Event Requiring Statement (MM/DD/YYYY)
1/1/2017 

3. Issuer Name and Ticker or Trading Symbol

Calithera Biosciences, Inc. [CALA]

(Last)        (First)        (Middle)

C/O CALITHERA BIOSCIENCES, INC., 343 OYSTER POINT BLVD. #200

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                            _____ 10% Owner
___ X ___ Officer (give title below)          _____ Other (specify below)
VP, RESEARCH /

(Street)

SOUTH SAN FRANCISCO, CA 94080       

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed (MM/DD/YYYY)

 

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person


Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock   12382   D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
STOCK OPTION (RIGHT TO BUY)     (1) 5/22/2023   COMMON STOCK   1979   $0.96   D    
STOCK OPTION (RIGHT TO BUY)     (2) 5/22/2023   COMMON STOCK   3116   $0.96   D    
STOCK OPTION (RIGHT TO BUY)     (3) 12/16/2023   COMMON STOCK   6246   $2.64   D    
STOCK OPTION (RIGHT TO BUY)     (4) 9/8/2024   COMMON STOCK   5688   $7.20   D    
STOCK OPTION (RIGHT TO BUY)     (5) 2/10/2025   COMMON STOCK   7000   $16.40   D    
STOCK OPTION (RIGHT TO BUY)     (6) 1/18/2026   COMMON STOCK   12000   $4.71   D    
STOCK OPTION (RIGHT TO BUY)     (7) 11/28/2026   COMMON STOCK   25000   $3.35   D    

Explanation of Responses:
( 1)  One-forty-eighth (1/48th) of the Option vests in equal monthly installments beginning November 15, 2012. The Option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company.
( 2)  One-forty-eighth (1/48th) of the Option vests in equal monthly installments one month after May 23, 2013. The Option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company.
( 3)  One-forty-eighth (1/48th) of the Option vests in equal monthly installments one month after December 17, 2013. The Option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company.
( 4)  One-forty-eighth (1/48th) of the Option vests in equal monthly installments one month after September 9, 2014. The Option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company.
( 5)  One-fourth (1/4th) of the Option vests one year after February 11, 2015; the balance of the Option vests in a series of thirty-six (36) successive equal monthly installments thereafter. The Option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company.
( 6)  One-fourth (1/4th) of the Option vests one year after January 19, 2016; the balance of the Option vests in a series of thirty-six (36) successive equal monthly installments thereafter. The Option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company.
( 7)  One-fourth (1/4th) of the Option vests one year after November 29, 2016; the balance of the Option vests in a series of thirty-six (36) successive equal monthly installments thereafter. The Option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Parlati Francesco
C/O CALITHERA BIOSCIENCES, INC.
343 OYSTER POINT BLVD. #200
SOUTH SAN FRANCISCO, CA 94080


VP, RESEARCH

Signatures
/s/ Francesco Parlati, Name: Francesco Parlati 1/6/2017
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Calithera Biosciences Charts.
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Calithera Biosciences Charts.